Teresa D. S. A.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Elranatamab Versus Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem-Cell Transplantation
- Phase 3 Randomized Trial of Teclistamab and Talquetamab Combinations Versus Standard Regimen in Newly Diagnosed Multiple Myeloma Ineligible for Transplant
Data & Insights
Has run more than one trial at 34 of 131 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of multiple myeloma, with particular emphasis on developing innovative therapeutic approaches for both newly diagnosed and transplant-eligible patients.
- Novel Treatment Combinations
- Post-Transplant Therapy
- Immunotherapy Applications
Their research encompasses evaluating novel therapeutic agents and combination strategies for hematologic malignancies.
Therapeutic Innovation
The investigator focuses on advancing targeted therapies through the evaluation of novel agents including elranatamab, teclistamab, and talquetamab in various therapeutic combinations.
- Comparative Treatment Studies
- Combination Therapy Development
- Treatment Optimization
Their work involves investigating optimal treatment sequences and combinations for enhanced patient outcomes.
Treatment Personalization
The investigator explores tailored therapeutic approaches for different patient populations, including those who are transplant-eligible and transplant-ineligible.
- Patient-Specific Approaches
- Treatment Strategy Development
- Clinical Outcome Assessment
Their research encompasses evaluating treatment efficacy across various patient subgroups and clinical scenarios.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.